Around 320 players from the Bavarian, German and international biotechnology sector attended the first biotechnology conference "BayOConnect - Forum for Biotech & LifeScience" in Munich, organized by the biotech cluster development organization BioM. On July 2 and 3, big players, SMEs, start-ups, academia, pharma, politics and investors came together to connect. The industry demonstrated the great innovation potential of artificial intelligence (AI) and data in medicine with concrete applications in practice. Start-ups presented new ideas on innovative therapies for cancer, hair loss and chronic lung diseases, among others. In addition, BioM presented its latest biotech report with current figures from the Bavarian biopharmaceutical industry.
It takes around 13 years from the idea to the approval of a drug. Artificial intelligence and data can significantly speed up ... [read more]
Supported by: